← All trials
NCT04083196
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 7, 2019
- Primary completion
- Mar 12, 2021
- Completion date
- Mar 12, 2021
- First posted
- —
- Last posted
- —
- Enrollment
- 90
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- National Vaccine and Serum Institute, ChinaLead sponsor
- Government of ChinaCollaborator
- Chengdu Institute of Biological Products Co.,Ltd.Collaborator
- Government of ChinaCollaborator
- Government of ChinaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.